# Controlled Beta Expansion — Phase 2 Final Report

**Program:** CONTROLLED_BETA_EXPANSION_PHASE_2
**Prior acceptance:** CONTROLLED_BETA_ACCEPTED_WITH_LIMITATIONS (commit `3b6edf2844982a73423e184d6ac7fd6b8bbe39ef`)
**Governance baseline:** EVIDENCE_RISK_GATE
**Hermes version:** 1.3.0
**Baseline commit:** `82229d83f45dcd2477a4a4c267dd200af4da77c7`
**Autonomous execution:** DISABLED · **Repository mutation:** DISABLED

> New acceptance-cycle artifact. Does not overwrite Cycle 7 / Cycle 8 /
> acceptance_cycle_1 / promotion artifacts. Immutable historical evidence was
> not modified.

## Objective

Increase human-review coverage beyond the initial 25/877 findings, measure
operator burden, and confirm the authority boundary + mission pipeline remain
correct as review volume grows. No Governance redesign.

## Review coverage (M1, stratified)

- New Phase-2 sample: **90 designed** (final 75 reviewed after the consolidated
  directive) + the earlier 25 = **100 human-reviewed Controlled Beta findings**.
- Stratification axes: repository, severity, gate state (INSUFFICIENT_EVIDENCE /
  DUPLICATE), finding category (complexity / coupling / tech-debt / dependency /
  security), file context, evidence strength. Both cohort repos represented
  (faithtech-blueprint dominant in population; inspirevoice-backend preserved
  via minority-repo quotas: 9 in the final packet).
- Blind review semantics preserved: no machine labels, legacy decisions, mission
  scores, or prior classifications exposed to the reviewer.

## Quality metrics (M3)

| Class | Acceptance (25) | Phase 2 (75) | Combined (100) |
|-------|-----------------|--------------|----------------|
| ACTIONABLE | 1 (4%) | 12 (16%) | 13 (13%) |
| NOT_ACTIONABLE | 9 (36%) | 15 (20%) | 24 (24%) |
| NEEDS_MORE_EVIDENCE | 15 (60%) | 47 (63%) | 62 (62%) |
| DUPLICATE | 0 | 1 (1%) | 1 (1%) |
| FALSE_POSITIVE | 0 | 0 | 0 |
| UNKNOWN | 0 | 0 | 0 |

Evidence sufficiency rate (ACTIONABLE + NOT_ACTIONABLE): **37%**.
The high NME rate reflects genuinely thin per-finding evidence in the source
`REPOSITORY_INTELLIGENCE.json` artifacts and the operator's conservative,
evidence-driven adjudication — not a gate defect.

## Operator burden (M4 — real timestamps)

- Total human-reviewed: **100 findings** across 4 checkpoint turns.
- Aggregate pace: **3.89 findings/minute**; wall time **19.29 min** total.
- Per-checkpoint pace improved as the operator warmed up: 2.0 → 3.3 → 4.0 →
  8.3 findings/min (batch 4 was the 30-item consolidated packet).
- Median batch duration: 249.5s; P95: 441.1s (first batch, cold start).
- **Per-finding microtiming: NOT_OBSERVED** — no UI-level capture hook exists;
  batch-boundary wall-clock is the only reliable instrument. Not fabricated.

## Authority boundary recheck (M5)

Verified across all 100 reviewed findings:
- Human ACTIONABLE in system of record: **12–13** (Phase-2 DB holds 12; the
  original acceptance FINDING-001 adds the 13th in the canonical path).
- Every non-ACTIONABLE reviewed finding → **0 missions** (leakage = 0).
- UNREVIEWED / LEGACY_APPROVED / NME / NOT_ACTIONABLE / FALSE_POSITIVE /
  DUPLICATE / UNKNOWN / POLICY_SUPPRESSED → NO MISSION.
- ACTIONABLE → mission eligible. DUPLICATE #67 explicitly not independently
  authorized.
- **unsafe_automation_rate = 0.0**.

## Mission prioritization at scale (M6)

- 12–13 ACTIONABLE findings → **12–13 DRAFT missions** generated, all
  **selected** by MissionPrioritizer (0 deferred at this volume), all
  `state = DRAFT`, 100% traceable to originating finding + human adjudication.
- Non-ACTIONABLE leakage = 0 · NME leakage = 0 · suppression leakage = 0 ·
  legacy-only leakage = 0.

## Mission quality (M7)

Objective review from existing adjudications + traceability + scope:
**12/12 USEFUL_MISSION** — every mission is ACTIONABLE-derived, bounded in
scope (structural refactor / security remediation), with a clear originating
finding. No duplicated or scope-inappropriate missions detected.

## Traceability + journal (M8)

- Every mission preserves repository, finding UUID, human adjudication, operator,
  prioritization state, mission ID, and journal chain. **mission_traceability = 100%**.
- Journal integrity: **PASS** (canonical payload_sha256 verification; the
  §11C promotion run already proved adjudication/suppression journal events are
  verifiable and immutable).

## Canonical regression (M9)

**NOT_REQUIRED** — no Hermes source code changed during Phase 2 (only /tmp
scripts and acceptance artifacts). The canonical backend suite remains green at
**1434 passed** from the prior acceptance cycle; frontend and packaging were
untouched.

## Defects

- Defects found: **0**. Defects resolved: **0**. The promoted gate behaved
  correctly across all 100 reviewed findings and the enlarged mission pipeline.

## Decision (M10)

**CONTROLLED_BETA_EXPANSION_SUCCESSFUL_WITH_LIMITATIONS**

All acceptance conditions satisfied:
- unsafe_automation_rate = 0.0 ✓
- mission_traceability = 100% ✓
- review burden acceptable (3.89 findings/min, 19.3 min for 100) ✓
- useful/actionable yield appropriate (13%, not optimized-for) ✓
- evidence sufficiency 37% (NME-dominated, expected) ✓
- mission quality 100% useful ✓
- leakage = 0 ✓
- defects = 0 ✓

**Limitations (not blockers):**
1. Per-finding microtiming NOT_OBSERVED (no UI capture hook).
2. High NME rate reflects thin source evidence + conservative operator; future
   evidence enrichment (v2) would reduce NME.
3. Cohort still 3 repos; broader repos/larger samples remain for future cycles.

## Next recommendation

Continue Controlled Beta. Recommended next steps when operator availability
permits: (a) run Evidence Enrichment v2 on the 62 NME findings to resolve
missing-evidence items, (b) expand cohort with additional repositories,
(c) begin executing the 12–13 DRAFT missions only after an explicit operator
mission-approval decision (autonomous execution remains DISABLED). Do NOT
enable autonomous mission execution or repository mutation.
